Addex Therapeutics Reports Stable Loss Per Share in First Half
Addex Therapeutics reported its first-half results for the six-month periods ended June 30, 2026 and 2025. The company noted that both basic and diluted loss per share remained stable at CHF 0.03 during this period. Additionally, cash and cash equivalents decreased to CHF 0.8 million as of June 2026 compared to previous levels. The financial results indicate a consistent performance in terms of earnings but highlight a reduction in available liquidity. This could raise concerns about the company’s ability to fund ongoing operations or future growth initiatives without additional financing, which may impact investor sentiment and stock valuation.
Tickers: $ADXN
Topics: cash_position loss_per_share